The Wolverine Stack: What It Is and What Has Been Tested

What the name refers to

"Wolverine stack" is not a clinical term, a protocol, or anything a researcher would recognize. It is a marketing name, borrowed from the comic-book character who heals fast, and it refers to taking BPC-157 and TB-500 together.

Neither compound is an approved drug. Neither is sold as a finished medicine. The name does the work that the evidence cannot: it tells you what to expect before anyone has measured whether that happens.

What has been tested — the combination

Nothing.

As of 14 August 2026, a search of ClinicalTrials.gov for "BPC-157 AND TB-500" returns zero registered studies. Not zero completed studies, not zero published results — zero records of anyone having registered an intention to test these two compounds together in humans.

That number means something only if the search works, so it was run alongside controls in the same pass: "BPC-157" alone returns 3 records, "TB-500" alone returns 1, and "semaglutide" returns 763. The query is capable of finding things. It finds nothing for the pair.

So every claim made for the stack as a stack — that the two work better together, that one covers what the other misses, that the combination is synergistic — is an assertion about an interaction nobody has studied. It might be true. There is no evidence either way, and "no evidence either way" is a different statement from "it works".

What has been tested — each compound alone

This is where the honest answer lives, and it is thinner than the marketing suggests.

BPC-157 has three registered records. ¹ Its literature is overwhelmingly animal work — three decades of it, mostly rodent, much of it from a small number of groups. A 2026 review in Pharmaceutics is candid about why that has not translated: the formulation, stability and delivery problems that stand between an interesting peptide and a usable drug remain unsolved. ¹ Read the full picture on the BPC-157 page.

TB-500 has one. ² And here is the distinction that most writing on this topic gets wrong, including much of what ranks for this term:

TB-500 is not thymosin β4. TB-500 is a short synthetic fragment. Thymosin β4 is the 43-residue parent protein.

The human trial record people cite for "TB-500" is almost entirely the parent, and mostly topical or ophthalmic — a phase 2 dry-eye trial, ³ a phase 1 safety study in healthy volunteers. ⁴ Those are real trials of a real molecule. They are not trials of the fragment sold under the TB-500 name, and treating them as interchangeable transfers a clinical record onto something that does not have one. The TB-500 page sets out what each actually covers.

Why "stacking" is the part with no evidence at all

Combining two compounds is not the same as using two compounds.

A combination can do less than either alone, or more, or something neither does — through competition for the same pathway, altered clearance, or an interaction nobody predicted. That is why combination trials exist as a category, and why regulators treat a fixed-dose combination as its own product requiring its own evidence rather than as the sum of two approvals.

For this pair, that work has not been started. There is no combination safety data, no interaction data, no dosing work, and no outcome measured in a person who took both.

What this page will not tell you

It will not tell you a dose, a schedule, a cycle length, or a source. Not because the information is hard to find, but because publishing it would be pretending to a level of knowledge that does not exist for a combination with zero registered trials.

If you are considering this, the useful questions are the ones a seller will not raise: what is actually in the vial, who tested it, what does the certificate of analysis say, and what does your clinician think about a combination with no published human safety record.

The short version

The wolverine stack is a name, not a protocol. Its two components have a thin human record each — three registered records for one, one for the other, and a widely-repeated confusion between TB-500 and its parent protein propping up the rest. The combination itself has never been registered as a trial in humans, checked on 14 August 2026 with working controls.

Anyone telling you what the stack does is telling you what they hope it does.